Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?

about

Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?

Item

http://www.wikidata.org/entity/Q41468057

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Is it a supplementary benefit ...... treatment of type 2 diabetes?

@en

type

Item

label

Is it a supplementary benefit ...... treatment of type 2 diabetes?

@en

prefLabel

Is it a supplementary benefit ...... treatment of type 2 diabetes?

@en

P1476

Is it a supplementary benefit ...... treatment of type 2 diabetes?

@en

P2093

Donkeng J Martial

http://www.w3.org/2001/XMLSchema#string

Nzogang K Patrice

http://www.w3.org/2001/XMLSchema#string

Telefo P Bruno

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

Type 2 diabetes as an inflammatory disease

Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.

A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria

Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

Type 2 diabetes mellitus: a metabolic autoinflammatory disease.

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.

Community-Based Culturally Preferred Physical Activity Intervention Targeting Populations at High Risk for Type 2 Diabetes: Results and Implications.

P2888

s13104-017-2785-4

P304

471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-017-2785-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091508854

http://www.w3.org/2001/XMLSchema#string

P698

28886725

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5591512

http://www.w3.org/2001/XMLSchema#string